Daily aspirin may ward off pancreatic cancer
the ONA take:
Daily intake of one low-dose aspirin over several years may be enough to lower your pancreatic cancer risk, according to a new study. The report supporting this conclusion was published online in the published online in the Cancer Epidemiology, Biomarkers & Prevention journal.
The researchers, led by lead researcher Dr. Harvey Risch, gathered data from 362 people diagnosed with pancreatic cancer and 690 with no history of pancreatic cancer. The cases observed spanned a four-year period from 2005 through 2009 and respondents were recruited from 30 Connecticut hospitals. Factors considered including when the patient began taking aspirin, history of diabetes (if any), smoking history (if any), and patient weight. For purposes of this study, a "low dose" of aspirin was quantified as anywhere from 75 milligrams to 325 milligrams. The observed reduction in pancreatic cancer risk varied, but increased the longer an individual respondent had been regularly taking aspirin; a 48-percent reduction was observed in individuals taking aspirin regularly for three years before the study, and the reduction grew to 60% for those taking aspirin for 20 years or more.
At this time the American Cancer Society has cautioned that evidence as to the cancer-preventive attributes of aspirin is limited. Although there is some connection between long-term aspirin use and lower risk of colorectal cancer, the Society does not feel current research data supports an recommendation for people to take aspirin daily for cancer prevention alone.
Aspirin and/or NSAID use may improve risk of high-grade prostate cancer
Even taking a daily aspirin for just three years lowered the chances of the deadly cancer by 48 percent, the researchers said.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|